Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides
出版年份 2013 全文链接
标题
Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 6, Pages 875-888
出版商
Informa Healthcare
发表日期
2013-03-02
DOI
10.1517/14712598.2013.774366
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys
- (2018) Elisabeth S. Hildebrandt-Eriksen et al. Nucleic Acid Therapeutics
- Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA).
- (2017) A. Y. Bedikian et al. JOURNAL OF CLINICAL ONCOLOGY
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
- (2012) Muthusamy Jayaraman et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Advanced morpholino oligomers: A novel approach to antiviral therapy
- (2012) Travis K. Warren et al. ANTIVIRAL RESEARCH
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Small heat shock proteins in cancer therapy and prognosis
- (2012) Amina Zoubeidi et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
- (2012) Nobutaka Hanagata International Journal of Nanomedicine
- Dose-response effects of TPI ASM8 in asthmatics after allergen
- (2011) G. M. Gauvreau et al. ALLERGY
- Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
- (2011) Jorge Cortes et al. CANCER
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study
- (2011) Aaron D. Schimmer et al. Clinical Lymphoma Myeloma & Leukemia
- Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models
- (2011) Martin J. O’Neill et al. DRUG DISCOVERY TODAY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- Antisense drug discovery and development
- (2011) Tsuyoshi Yamamoto et al. Future Medicinal Chemistry
- Chemical and Mechanistic Toxicology Evaluation of Exon Skipping Phosphorodiamidate Morpholino Oligomers in mdx Mice
- (2011) Peter Sazani et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy
- (2011) Peter Sazani et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- The long march of antisense
- (2011) Dan Jones NATURE REVIEWS DRUG DISCOVERY
- Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
- (2011) Nathalie M. Goemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
- (2011) Erich Koller et al. NUCLEIC ACIDS RESEARCH
- Delivery of siRNA Therapeutics: Barriers and Carriers
- (2010) Jie Wang et al. AAPS Journal
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy
- (2010) Hong M. Moulton et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
- (2010) Srikala S. Sridhar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Off-Target Effects Related to the Phosphorothioate Modification of Nucleic Acids
- (2010) Johannes Winkler et al. ChemMedChem
- Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development
- (2010) S. Hartwig et al. DEVELOPMENT
- Morpholino artifacts provide pitfalls and reveal a novel role for pro-apoptotic genes in hindbrain boundary development
- (2010) Sebastian S. Gerety et al. DEVELOPMENTAL BIOLOGY
- Akt inhibitors in clinical development for the treatment of cancer
- (2010) Sumanta Kumar Pal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mipomersen as a potential adjunctive therapy for hypercholesterolemia
- (2010) Neeraj Patel et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety Pharmacology and Genotoxicity Evaluation of AVI-4658
- (2010) Peter Sazani et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics
- (2010) Long Xu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Safety signal dampens reception for mipomersen antisense
- (2010) Jim Kling NATURE BIOTECHNOLOGY
- Rational design of cationic lipids for siRNA delivery
- (2010) Sean C Semple et al. NATURE BIOTECHNOLOGY
- Advanced antisense therapies for postexposure protection against lethal filovirus infections
- (2010) Travis K Warren et al. NATURE MEDICINE
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic
- (2009) Sam Maher et al. ADVANCED DRUG DELIVERY REVIEWS
- Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection
- (2009) D. L. Swenson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers
- (2009) Patrick Iversen et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Inhibition of Protein Tyrosine Phosphatase-1B with Antisense Oligonucleotides Improves Insulin Sensitivity and Increases Adiponectin Concentrations in Monkeys
- (2009) Michael M. Swarbrick et al. ENDOCRINOLOGY
- Antisense oligonucleotide pharmacokinetics and metabolism
- (2009) Richard S Geary Expert Opinion on Drug Metabolism & Toxicology
- Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides
- (2009) Paul J. White et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Oral delivery of siRNA and antisense oligonucleotides
- (2009) Saghir Akhtar JOURNAL OF DRUG TARGETING
- In vivocomparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
- (2009) Hans A. Heemskerk et al. JOURNAL OF GENE MEDICINE
- A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells
- (2009) Martina Stessl et al. Journal of Proteomics
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
- (2009) Maria Kinali et al. LANCET NEUROLOGY
- Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
- (2009) R. Juliano et al. MOLECULAR PHARMACEUTICS
- Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos
- (2009) Jon Moulton et al. MOLECULES
- Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
- (2009) C. A. Stein et al. NUCLEIC ACIDS RESEARCH
- Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
- (2009) R. E. Lanford et al. SCIENCE
- A Primer for Morpholino Use in Zebrafish
- (2009) Brent R. Bill et al. Zebrafish
- Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications
- (2008) M. Pisano et al. ANNALS OF ONCOLOGY
- Antisense Treatment for Myasthenia Gravis
- (2008) Jon D. Sussman et al. Annals of the New York Academy of Sciences
- Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
- (2008) Rosie Z. Yu et al. BIOCHEMICAL PHARMACOLOGY
- Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos into a wide array of mouse tissues
- (2008) Paul A. Morcos et al. BIOTECHNIQUES
- Nucleic Acids as Therapeutic Agents
- (2008) Luis Alvarez-Salas CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Specific VDAC inhibitors: phosphorothioate oligonucleotides
- (2008) C.A. Stein et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- Comparing In Vitro and In Vivo Activity of 2′-O-[2-(Methylamino)-2-oxoethyl]- and 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
- (2008) Thazha P. Prakash et al. JOURNAL OF MEDICINAL CHEMISTRY
- Short Antisense Oligonucleotides with Novel 2′−4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
- (2008) Punit P. Seth et al. JOURNAL OF MEDICINAL CHEMISTRY
- A RNA antagonist of hypoxia-inducible factor-1 , EZN-2968, inhibits tumor cell growth
- (2008) L. M. Greenberger et al. MOLECULAR CANCER THERAPEUTICS
- Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates
- (2008) Alain Guimond et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started